16th week of 2014 patent applcation highlights part 42 |
Patent application number | Title | Published |
20140105913 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS - IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases. | 2014-04-17 |
20140105914 | HUMANISED ANTI CTLA-4 ANTIBODIES - The invention provides an anti-CTLA4 antibody which inhibits the binding of CTLA4 to human B7, in particular, it inhibits binding of CTLA4 to human B7.1 and/or human B7.2. Specific antibodies are provided with specific variable region sequences as well as compositions comprising such antibodies for use in treating disease. | 2014-04-17 |
20140105915 | BCMA (CD269/TNFRSF17) - BINDING PROTEINS - The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods. | 2014-04-17 |
20140105916 | HUMAN C-FMS ANTIGEN BINDING PROTEINS - Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages. | 2014-04-17 |
20140105917 | FRIZZLED-BINDING AGENTS AND USES THEREOF - Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided. | 2014-04-17 |
20140105918 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS - The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer. | 2014-04-17 |
20140105919 | SYNERGISTIC INHIBITION OF ERBB2/ERBB3 SIGNAL PATHWAYS IN THE TREATMENT OF CANCER - Methods for treating tumors comprising cells overexpressing ErbB2 or ErbB3 are provided, and comprise inhibiting the biologic activity of one or more of ErbB2 and ErbB3 in the cells and inhibiting the expression or the biologic activity of a constituent of a signal pathway connected with ErbB2 or ErbB3 signaling. | 2014-04-17 |
20140105920 | COMPOSITIONS AND METHODS TO TREAT DISEASE CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS - Described herein are compositions and methods for preventing and/or treating diseases involving aberrant angiogenesis employing one or more benzo[c]chromen-6-one derivatives. | 2014-04-17 |
20140105921 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors - This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors. | 2014-04-17 |
20140105922 | Variant Target Binding Agents and Uses Thereof - The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells. | 2014-04-17 |
20140105923 | TUMOR ANTIGEN PROTEINS OR GENES OF POLO-LIKE KINASE 1 - The present invention relates to tumor antigen proteins or genes derived from polo-like kinase 1. As a result of the formation of a complex by binding polo-like kinase 1-derived proteins or variants having characteristics functionally identical to the proteins with MHC class I antigens or II antigens, the complex can be recognized by cytotoxic T lymphocytes. Therefore, the polo-like kinase 1-derived proteins or variants are identified as a tumor antigen which can be generally used in tumor immunotherapy. | 2014-04-17 |
20140105924 | Immunogenic HPV L2-Containing VLPs and Related Compositions, Constructs, and Therapeutic Methods - The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection. | 2014-04-17 |
20140105925 | Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of Dengue Virus Infection - Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHR) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. The present invention incorporates immunoproteomics to uncover novel HLA-A2 specific epitopes derived from Dengue Virus (DV)-infected cells. These epitopes are conserved with epitope-specific CTLs cross-reacting against all four DV serotypes. These epitopes have potential as new informational and diagnostic tools to characterize T cell immunity in Dengue virus (DV) infection, and serves as a universal vaccine candidate complementary to current vaccines. | 2014-04-17 |
20140105926 | IMMUNOGENIC COMPOSITION - The present invention relates to immunogenic compositions comprising one or more | 2014-04-17 |
20140105927 | IMMUNOGENIC COMPOSITION - The present invention relates to an immunogenic composition comprising
| 2014-04-17 |
20140105928 | Antiviral and antibacterial activity from medicinal mushrooms - Compounds having unique antiviral and antibacterial properties are prepared from medicinal mushroom mycelium, extracts and derivatives. The compositions are derived from | 2014-04-17 |
20140105929 | USE OF SARGASSUM CRISTAEFOLIUM EXTRACT | 2014-04-17 |
20140105930 | BOVINE VACCINES AND METHODS - Methods for stimulating immune responses in a bovine animal susceptible to infection by | 2014-04-17 |
20140105931 | HEPATITIS C VIRUS PARTICLES, VACCINES, COMPOSITIONS AND METHODS RELATED THERETO - This disclosure relates to viral particles and nucleic acids encoding an HCV envelope glycoprotein 2 containing a mutation. Viral particles can be created and administered to a subject to illicit an immune response. | 2014-04-17 |
20140105932 | MULTIVALENT [BETA] - 1 - 2 - LINKED MANNOSE OLIGOSACCHARIDES AS IMMUNOSTIMULATORY COMPOUNDS AND USES THEREOF - This invention relates to synthetic oligo- or multivalent beta-1-2-linked mannooligosaccharide compounds and to their use for modulating T helper (Th) and T regulatory (Treg) cell-mediated immune responses. | 2014-04-17 |
20140105933 | METHODS FOR ASSESSING CANCER RECURRENCE - Certain embodiments are directed to methods of identifying a subject having a higher risk of prostate cancer recurrence. The methods can include the step of measuring levels of one or more of FLIP, transcription factor Sp1, and transcription factor Sp3 in a prostate sample from the subject, wherein elevated levels of FLIP, transcription factor Sp1, and transcription factor Sp3 identify a subject as high risk for prostate cancer recurrence. | 2014-04-17 |
20140105934 | METHOD FOR ENHANCING IMMUNE RESPONSE IN THE TREATMENT OF INFECTIOUS AND MALIGNANT DISEASES - The present invention pertains to a new approach for the treatment of infectious and malignant diseases. The present invention provides new DNA and protein vaccines for the treatment of infectious and malignant diseases through enhancing immune response. | 2014-04-17 |
20140105935 | OPSONIZED BETA-GLUCAN PREPARATION AND METHODS - Described herein are compositions that include isolated opsonized soluble β-glucan, methods of making those compositions and methods of using those compositions. | 2014-04-17 |
20140105936 | PHARMACEUTICAL COMPOSITION FOR THE PREPARATION OF INFUSION SOLUTIONS OF ANTIMICROBIAL PREPARATIONS, ITS PRODUCTION PROCESS (variations) - The proposed compositions and methods for preparation thereof relate to pharmacology, medicine, veterinary science and pharmaceutical industry. The compositions can be used for preparing infusion solutions of antimicrobial (antibacterial and antifungal) preparations increasing therapeutic efficiency thereof. The compositions include nanostructured colloidal silica and are efficient when treating overwhelming sepsis of tested animals, provoked by Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Candida albicans. The pharmaceutical compositions have a proven and significant clinically important potentiating impact on therapeutic efficiency of the infusion solutions, when treating inflammatory diseases, in comparison with traditional solvents. The methods include—obtaining a mixture of colloidal silica with sodium chloride or with dextrose in a certain weight ratio, which mixture includes a mass fraction of fine-dispersed particles of colloidal silica, having dimensions not exceeding 5 micrometers, and —subjecting the mixture to impacting-abrasive actions, until the mass fraction is increased at least twice. | 2014-04-17 |
20140105937 | TOPICAL UBIQUINOL ORAL SUPPLEMENT COMPOSITIONS WITH AMORPHOUS CALCIUM PHOSPHATE - Topical, UBIQUINOL, adjunctive, supplement compositions, containing amorphous calcium phosphate fluoride (ACPF), useful in: reducing oxidative stress, relieving oral discomfort and dry mouth, and remineralizing hydroxyapatite; comprising: UBIQUINOL in an aqueous-free emulsion that also contains: a stabilizing composition for UBIQUINOL, spilanthes extract, a trans-oral mucosal, absorption facilitator and ACPF; wherein: the emulsion forms a mucoadhesive gel in the presence of saliva that undergoes gradual saliva dissolution effecting passive diffusion of the UBIQUINOL supplement and the spilanthes extract into the oral mucosa, and remineralizing of tooth surfaces with ACPF; resulting in: adjunctively increasing UBIQUINOL levels, reducing oxidative stress, regulating immune response, relieving oral discomfort and dry mouth, and remineralizing tooth surfaces. | 2014-04-17 |
20140105938 | CARTILAGE CELL PROCESSING SYSTEM - An automated or semi-automated module-based cartilage cell processing device ( | 2014-04-17 |
20140105939 | METHODS AND COMPOSITIONS FOR MODULATING MYOFIBROBLAST ACTIVITIES - The present invention discloses methods and compositions for treating or ameliorating a condition associated with increased or decreased myofibroblast activities and use thereof | 2014-04-17 |
20140105940 | BIOCOMPATIBLE MATERIAL AND USES THEREOF - The present invention relates to a biocompatible material and in particular to a two-phase or composite biocompatible ceramic material, wherein the first phase is a doped calcium zinc silicate and the second phase is a metal oxide. In an embodiment, the invention has been developed for use in tissue regeneration including bone tissue. In other embodiments, the invention has been developed as a coating to improve the long-term stability of prior art implantable medical devices. | 2014-04-17 |
20140105941 | Remineralizing and Desensitizing Compositions, Treatments and Methods of Manufacture - Improved remineralizing and desensitizing compositions containing remineralizing ingredients in aqueous-free emulsions that, in the presence of saliva, form mucoadhesive gels substantive to tooth surfaces; wherein the gels are dissolved by saliva gradually releasing remineralizing ingredients onto tooth surfaces, treatments with these compositions and methods of manufacture. | 2014-04-17 |
20140105942 | AQUEOUS WAX DISPERSIONS - The present invention is directed to an aqueous dispersion comprising: (a) at least one solid wax particle having a particle size ranging from equal to or greater than 1 micron to about 100 microns and comprising at least one wax having a melting point of greater than 35° C.; (b) a surfactant mixture comprising at least one nonionic surfactant and at least one ionic surfactant; and (c) water. The aqueous dispersion may be employed in compositions capable of delivering benefits to various substrates, for example, keratinous substrates such as skin and hair. | 2014-04-17 |
20140105943 | AQUEOUS WAX DISPERSIONS CONTAINING SUNSCREEN AGENTS - The present invention is directed to an aqueous dispersion comprising: (a) at least one solid wax particle having a particle size ranging from equal to or greater than 1 micron to about 100 microns, and comprising at least one wax having a melting point of greater than 35° C.; (b) a surfactant mixture comprising at least one nonionic surfactant and at least one ionic surfactant; (c) at least one sunscreen agent; and (d) water. The aqueous dispersion may be employed in compositions capable of delivering photoprotective benefits to various substrates, for example, keratinous substrates such as skin and hair. | 2014-04-17 |
20140105944 | AQUEOUS WAX DISPERSIONS CONTAINING VOLATILE SOLVENTS - The present invention is directed to an aqueous dispersion comprising: (a) at least one solid wax particle having a particle size ranging from equal to or greater than 1 micron to about 100 microns and comprising at least one wax having a melting point of greater than 35° C.; (b) a surfactant mixture comprising at least one nonionic surfactant and at least one ionic surfactant; (c) at least one volatile solvent; and (d) water. The aqueous dispersion may be employed in compositions capable of delivering benefits to various substrates, for example, keratinous substrates such as skin and hair. | 2014-04-17 |
20140105945 | COSMETIC COMPOSITIONS COMPRISING WAX DISPERSIONS AND THERMOREVERSIBLE GELLING POLYMERS - The disclosure relates to compositions comprising at least one film former, at least one wax dispersion, and at least one thermoreversible gelling polymer. The disclosure further relates to methods of increasing the volume of keratinous fibers, and methods of improving the ease of removability of compositions. | 2014-04-17 |
20140105946 | PERSONAL CARE COMPOSITION IN THE FORM OF A DISSOLVABLE ARTICLE - An article that is a porous, dissolvable solid structure that dissolves easily due to the shape, product orientation and/or method of manufacturing the porous, dissolvable solid structure. The process of making the Article involves preparing a pre-mixture, aerating the pre-mixture, dosing the pre-mixture into individual cavities in molds, and drying the pre-mixture to an Article having an open celled foam with a % open cell of from about 80% to about 100%. | 2014-04-17 |
20140105947 | NATURAL ESTER, WAX OR OIL TREATED PIGMENT, PROCESS FOR PRODUCTION THEREOF, AND COSMETIC MADE THEREWITH - The present invention provides compositions for natural cosmetic products and, more particularly, to natural ester, wax or oil treated pigments, the products of such treated pigments and cosmetic products incorporating pigments treated with natural ingredients. | 2014-04-17 |
20140105948 | STABILITY OF PEROXIDE IN ORAL CARE COMPOSTIONS - The present invention is directed to a product and method for providing tooth whitening to a user. In particular, the invention is directed to a chewing gum product including an encapsulated solid peroxide composition. | 2014-04-17 |
20140105949 | COMPOSITION FOR EXTERNAL USE AND METHOD FOR PRODUCING THE SAME - A composition for external use containing a physiologically acceptable salt of a tranexamate as an active ingredient, which is dispersed in the composition in the state of fine particles, is provided. Thereby, a physiologically acceptable salt of the tranexamate is dissolved in a solvent to prepare a solution, to which a salting-out agent is added to precipitate the salt. Such salt is so dispersed in a composition for external use in the state of fine particles that the tranexamate salt can be mixed without using a large amount of an oil component to obtain a composition for external use affording excellent feel of use and stability. | 2014-04-17 |
20140105950 | HAEMOSTATIC MATERIAL - The present invention relates to a haemostatic material comprising a haemostat agent and a bioadhesive agent. Such a haemostatic material is useful, for example, in effectively controlling bleeding with a reduced compression period compared to the guidance of a minimum of three minutes compression using a haemostatic bandage. | 2014-04-17 |
20140105951 | SERICIN EXTRACTED FABRICS - Silk is purified to eliminate immunogenic components (particularly sericin) and is used to form fabric that is used to form tissue-supporting prosthetic devices for implantation. The fabrics can carry functional groups, drugs, and other biological reagents. Applications include hernia repair, tissue wall reconstruction, and organ support, such as bladder slings. The silk fibers are arranged in parallel and, optionally, intertwined (e.g., twisted) to form a construct; sericin may be extracted at any point during the formation of the fabric, leaving a construct of silk fibroin fibers having excellent tensile strength and other mechanical properties. | 2014-04-17 |
20140105952 | CARBONYL CONTAINING COMPOUNDS FOR CONTROLLING AND REPELLING CIMICIDAE POPULATIONS - Compositions and methods for controlling and/or repelling bedbugs are provided. The compositions comprise one or more compounds having bedbug repellant activity. Such compounds may be, for example, naturally occurring semiochemicals or structural or functional analogs of naturally occurring semiochemicals. Exemplary compounds are compounds of general formula (I). | 2014-04-17 |
20140105953 | ANTIMICROBIAL GLASS-CERAMICS - The application discloses the formation of antimicrobial glass-ceramic articles having an amorphous phase and a crystalline phase and an antimicrobial agent selected from the group consisting of silver, copper and a mixture of silver and copper. The antimicrobial glass-ceramic can have a Log Reduction of >2. | 2014-04-17 |
20140105954 | LAYERED SCAFFOLD SUITABLE FOR OSTEOCHONDRAL REPAIR - The invention relates to a method for producing a multi-layer collagen scaffold. The method generally comprises the steps of: preparing a first suspension of collagen and freezing or lyophilising the suspension to provide a first layer; optionally preparing a further suspension of collagen and adding the further suspension onto the layer formed in the previous step to form a further layer, and freezing or lyophilising the layers, wherein when the layer formed in the previous step is formed by lyophilisation the lyophilised layer is re-hydrated prior to addition of the next layer; optionally, repeating the aforementioned step to form one or more further layers; and preparing a final suspension of collagen and pouring the final suspension onto the uppermost layer to form a final layer, and freeze-drying the layers to form the multi-layer collagen composite scaffold. | 2014-04-17 |
20140105955 | THERMOPLASTIC FLUOROPOLYMER-COATED MEDICAL DEVICES - A medical device provided with at least a partial surface coating of a thermoplastic copolymer of tetrafluoroethylene and perfluoroalkylvinylether that is free of cross-linking monomers and curing agents. The fluoropolymer coating is preferably an amorphous thermoplastic, is highly inert and biocompatible, has elastomeric characteristics that provide desirable mechanical properties such as good flexibility and durability. These characteristics allow the coating to be considered “functionally transparent” because it withstands mechanical deformations required for the assembly, deployment, expansion, and placement of medical devices, without any adverse effect on the mechanical and biological functionality of the coated device. Further, its inertness, derived from the perfluorocarbon structure, contributes to its functionally transparent nature. The coating can be provided with various liquid or solid additives, can be loaded with large quantities of additives including a wide range of therapeutic agents, and has excellent drug elution characteristics when elutable additives are used. | 2014-04-17 |
20140105956 | BIODEGRADABLE POLYMER BASED MICROIMPLANT FOR OCULAR DRUG DELIVERY - Novel sustained release biodegradable implants and methods of making and of using the same to treat ocular diseases are provided. | 2014-04-17 |
20140105957 | BIS-(ALPHA-AMINO-DIOL-DIESTER) CONTAINING POLYESTERAMIDE FOR OPHTAMOLOGY - The present invention relates to an ocular polymer delivery composition comprising at least one ophthalmologic agent dispersed in at least one biodegradable polymer, wherein the polymer comprises at least one of a poly (ester amide) (PEA) having a chemical formula described by structural formula (I). | 2014-04-17 |
20140105958 | EDIBLE STICKER WITH NUTRIENT - An edible sticker including an edible paper, an edible ink, and an edible compound on at least a portion of the edible paper. The edible compound includes one selected from a nutrient, a supplement, a medicine, a mineral, a flavoring, a vitamin, and combinations thereof. A method of providing nutrients to a child using the edible sticker, a method of manufacturing the edible sticker, and a system for manufacturing the edible sticker have also been disclosed. | 2014-04-17 |
20140105959 | METHOD AND DEVICE FOR REDUCING DERMAL FILLER ADVERSE EVENTS - Methods and devices of aesthetically enhancing and improving appearance of aging skin are provided. Methods may include the steps of treating a skin site selected for dermal filler administration with a mechanism effective to enhance drug delivery across the skin, applying to the treated site, a device, compound or formulation including an active agent effective to reduce visible bruising due to administration of a dermal filler into the site, and administering a dermal filler into the skin site thereby reduce the appearance of wrinkles or folds in the skin site without causing significant bruising. Devices for reducing or ameliorating adverse events from dermal filler administration are also included. | 2014-04-17 |
20140105960 | HYDROGELS FOR TISSUE REGENERATION - Provided herein are hydrogels and hydrogel-forming compositions that are useful for, among others, tissue regeneration in vivo. Methods for generating such hydrogels, for example, from such hydrogel-forming compositions are also provided herein. Therapeutic methods employing hydrogels and hydrogel-forming composition, for example, for restoration of tissue perfusion in the context of acute ischemia, are also provided. The disclosure also describes kits comprising components useful for generating hydrogels as described herein. | 2014-04-17 |
20140105961 | IMMUNOMODULATION USING SPORES AND POLLEN GRAINS - The present invention includes compositions, methods of making and using the compositions for modulating the immune response in a subject by providing a vaccine composition having a pollen/spore disposed in a pharmaceutical carrier for delivery to a subject, wherein the pollen/spore comprises multiple pores that connect an outer surface of the pollen/spore to an inner cavity and one or more antigens disposed on the outer surface, in the inner cavity, in the multiple pores, or a combination thereof, wherein the one or more antigens modulate an immune responses in the subject. | 2014-04-17 |
20140105962 | MERRIMIA TRIDENTATA COMPOSITIONS - A composition including a powder or extract of Merremia Tridentata mixed with a liposome carrier. The liposome carrier may be a lotion, cream or suspension. The composition may be used to treat Osteophytes of the spine, feet, hands, and knees. | 2014-04-17 |
20140105963 | TOPICAL NITRIC OXIDE SYSTEMS AND METHODS OF USE THEREOF - The present invention generally relates to compositions and methods for transdermal drug delivery. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction, treating wounds, or causing or promoting hair growth. For example, in one aspect, the present invention is generally directed to compositions for delivery of nitric oxide, transdermally and/or to a mucosal surface. The composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. In some embodiments, a composition comprising nitric oxide is unexpectedly stable and can be stored long-term. | 2014-04-17 |
20140105964 | MODIFIED POLYNUCLEOTIDES ENCODING AQUAPORIN-5 - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 2014-04-17 |
20140105965 | MODIFIED POLYNUCLEOTIDES ENCODING COPPER METABOLISM (MURR1) DOMAIN CONTAINING 1 - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 2014-04-17 |
20140105966 | MODIFIED POLYNUCLEOTIDES ENCODING HEPATITIS A VIRUS CELLULAR RECEPTOR 2 - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 2014-04-17 |
20140105967 | STABILIZED COMPOSITION AND METHOD FOR DERMATOLOGICAL TREATMENT - A stabilized, topical composition for the treatment of acne and other dermatological conditions comprises a liposomal formulation of a retinoid and an antibiotic in which the retinoid is disposed in the lipid phase of the formulation, and the antibiotic is disposed in the aqueous phase so as to be isolated from the retinoid. Lincosamides, such as clindamycin, are one group of antibiotics which may be used in the composition. Tretinoin is one preferred retinoid. Also disclosed are methods for making the compositions and methods for using the composition. | 2014-04-17 |
20140105968 | TRANSPULMONARY LIPOSOME FOR CONTROLLING DRUG ARRIVAL - An object of the present invention is to provide a liposome which is excellent in intrapulmonary delivery controllability of drugs or genes and is suited for pulmonary administration. | 2014-04-17 |
20140105969 | Compositions and Methods for Treating Cancer - The present invention provides, in part, compositions and methods for treating cancer using a combination of C6-ceramide and other anti-cancer agents. | 2014-04-17 |
20140105970 | ADJUVANT AND ANTIGEN PARTICLE FORMULATION - A composition as disclosed is comprised of a plurality of particles and a pharmaceutically acceptable carrier. The particles are comprised of (1) an adjuvant; (2) a biocompatible polymer which maybe a co-polymer such as PLGA, and (3) a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. The carrier includes an adjuvant such as a monophosphoryl lipid A (MPL) different from the adjuvant in the particles. The particles may be sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell. | 2014-04-17 |
20140105971 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA IN HYPERCALCEMIC PATIENTS AND IMPROVED CALCIUM-CONTAINING COMPOSITIONS FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel calcium-containing microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without removing calcium from the patient's body. Also disclosed are methods of using calcium-free or low calcium microporous zirconium silicate compositions for the treatment of hyperkalemia in patients also suffering from hypercalcemia. | 2014-04-17 |
20140105972 | PREVOTELLA HISTICOLA PREPARATIONS AND THE TREATMENT OF AUTOIMMUNE CONDITIONS - This document provides methods and materials related to | 2014-04-17 |
20140105973 | METHOD OF TREATING A DISEASE CONDITION SUSCEPTIBLE TO BACLOFEN THERAPY - The present invention discloses a method of treating a disease condition susceptible to baclofen therapy, said method comprising orally administering once-a-day in the evening a controlled release drug delivery system comprising baclofen or its pharmaceutically acceptable salt or its derivatives and pharmaceutically acceptable excipients. | 2014-04-17 |
20140105974 | COMPOSITIONS FOR ENCAPSULATING BIOMATERIALS AND USES RELATED THERETO - This disclosure relates to compositions and methods for encapsulating biomaterials such as cells to prevent immune responses. In certain embodiments the disclosure relates to capsules comprising a cell or cells gelled in alginate coated with a layer that prevents migration of immune molecules to the cell surface and an outer capsule layer comprising non-immunogenic material optionally containing immunosuppressive agents. In certain embodiments, the cells are capable of generating insulin that emanates from the capsule. | 2014-04-17 |
20140105975 | FILM COATING FOR TABLETS AND CAPLETS - The present invention relates to novel coating compositions for application to solid dosage forms such as tablets or caplets, solid dosage forms coated with the composition, and methods of preparing said coating compositions. | 2014-04-17 |
20140105976 | PHARMACEUTICAL FORMULATIONS OF PILOCARPINE - Disclosed herein are pharmaceutical compositions comprising at least one minitablet, where the minitablet comprises a core, comprising pilocarpine, or a pharmaceutically acceptable salt thereof; and a coating layer comprising a coating polymer. | 2014-04-17 |
20140105977 | GASTRIC RETENTIVE EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS - The present disclosure provides extended release pharmaceutical compositions comprising an opioid and an additional active pharmaceutical ingredient, wherein the composition exhibits gastric retentive properties which are achieved by a combination of a physical property of the composition and release of the opioid, wherein upon administration to a subject, the composition has at least one pharmacokinetic parameter that differs by less than about 30% when the subject is in a fasted state as compared to a fed state. | 2014-04-17 |
20140105978 | SILK MICROSPHERES FOR ENCAPSULATION AND CONTROLLED RELEASE - A method was developed to prepare silk fibroin microspheres using lipid vesicles as templates to efficiently load therapeutic agents in active form for controlled release. The lipids are subsequently removed through the use of a dehydration agent, such as methanol or sodium chloride, resulting in β-sheet structure dominant silk microsphere structures having about 2 μm in diameter. The therapeutic agent can be entrapped in the silk microspheres and used in pharmaceutical formulations for controlled-release treatments. | 2014-04-17 |
20140105979 | COMPOSITIONS AND METHODS FOR THE TRANSDERMAL DELIVERY OF METHYLPHENIDATE - Compositions for the transdermal delivery of methylphenidate in a flexible, finite form are described. The compositions comprise a polymer matrix that includes methylphenidate or a pharmaceutically acceptable salt and at least one acrylic polymer that is non-reactive with methylphenidate. Methods using the compositions to achieve transdermal delivery of methylphenidate or for treating Attention Deficit Disorder (ADD) and/or Attention Deficit/Hyperactivity Disorder (ADHD), postural orthostatic tachycardia syndrome, or narcolepsy also are described. | 2014-04-17 |
20140105980 | METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS AND RELATED DISORDERS - This disclosure provides therapeutic compositions and methods for treating multiple sclerosis or a multiple sclerosis-related disorder in a subject in need thereof comprising administering an effective amount of an antigen-MHC-nanoparticle complex to the subject, wherein the antigen is a multiple sclerosis-related antigen. | 2014-04-17 |
20140105981 | PREVENTATIVE SOLUTION AND METHOD OF USE - A preventative solution includes an aqueous base, 1 wt % to 6 wt % titanium dioxide having an average particle size of not greater than 100 nm, 0.5 wt % to 20 wt % alcohol having 2 to 4 carbons, and 3 wt % to 15 wt % of a binding agent. The preventative solution can be dispersed using a fogger, for example, sequentially with an odor neutralizing solution or a disinfectant solution. | 2014-04-17 |
20140105982 | SILVER NANOPLATE COMPOSITIONS AND METHODS - Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoplates, such as silver nanoplates or silver platelet nanoparticles, and to nanoparticles, solutions and substrates prepared by said methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates. The process can also include increasing the concentration of silver nanoplates within the solution, and thus increasing the solution optical density. | 2014-04-17 |
20140105983 | Pulmonary Delivery for Levodopa - In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung. | 2014-04-17 |
20140105984 | REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS - This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm. | 2014-04-17 |
20140105985 | TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION - The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided. | 2014-04-17 |
20140105986 | TOPICAL COMPOSITIONS - Provided herein are anhydrous compositions that include at least one viscosity increasing agent, at least one organic solvent and at least one humectant. Such compositions may also include at least one active pharmaceutical ingredient (API) and/or at least one water repellant. Related compositions, methods and kits are also provided. | 2014-04-17 |
20140105988 | GRANULATED MATERIAL MIXTURE COMPRISING TWO DIFFERENT GRANULATED MATERIALS FOR ARTIFICIAL CALLUS DISTRACTION - A granulate mixture suitable for regenerating a bone contains at least one expandable particle and at least one nondeformable particle. The at least one expandable particle contains a swelling agent. The swelling is enclosed by a biodegradable sheathing or be a biodegradable casing. Three-dimensional callus distraction may be accomplished by introducing the granulated mixture into a bone defect. | 2014-04-17 |
20140105989 | Treatment Methods with Low-Dose, Longer-Acting Formulations of Local Anesthetics and Other Agents - Drug formulations that provide sustained action and/or reduced dosage requirements are provided. In the formulations the drugs (particularly local anesthetics) are associated with reversed cubic phase and reversed hexagonal phase lyotropic liquid crystalline material. | 2014-04-17 |
20140105990 | USE OF EPIDERMAL GROWTH FACTOR FOR THE MORPHOFUNCTIONAL RESTORATION OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY - The present invention is relevant to human medicine, and, in particular, to the use of Epidermal Growth Factor (EGF) in a pharmaceutical composition, said composition is administered through infiltration at the periphery of nerve trunks and/or ganglia, for the morphofunctional restoration of peripheral nerves in painful, sensitive-motor neuropathy, as well as ischemic neuritis. It is also relevant to an EGF containing composition, where this molecule can be formulated together with anesthetic or analgesic drugs, or encapsulated in microspheres, and their use for the morphofunctional restoration of peripheral nerves in painful, sensitive-motor neuropathy, as well as in ischemic neuritis. | 2014-04-17 |
20140105991 | SPHERICAL MICROCAPSULES COMPRISING GLP-1 PEPTIDES, THEIR PRODUCTION AND USE - The present invention provides spherical microcapsules comprising at least one surface coating and a core, wherein the at least one surface coating comprises cross-linked polymers, and wherein the core comprises cross-linked polymers and cells capable of expressing and secreting a GLP-1 peptide, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof. The present applicators is furthermore directed to methods for production of these spherical microcapsules and to the use of these microcapules e.g. in the treatment of type 2 diabetes, weight disorders and diseases or conditions associated thereto, neurodegenerative disorders and diseases or conditions associated thereto, or for the treatment of disorders and diseases or conditions associated to apoptosis. | 2014-04-17 |
20140105992 | VACCINE - The present provide vaccine and adjuvant formulation comprising an immunostimulant and a metal salt. The immunostimulant is adsorbed on to a particle of metal salt and the resulting particle is essentially devoid of antigen. | 2014-04-17 |
20140105993 | MODIFIED-RELEASE MICROPARTICLES BASED ON AMPHIPHILIC COPOLYMER AND ON ACTIVE PRINCIPLE(S) AND PHARMACEUTICAL FORMULATIONS COMPRISING THEM - The present invention relates to novel microparticles formed of amphiphilic polyamino acids which transport active principle(s), AP(s), in particular protein and peptide active principle(s), and to novel modified-release pharmaceutical formulations comprising said AP microparticles. Microparticles of amphiphilic polyamino acid (PO) may include at least one AP (associated noncovalently) which spontaneously form a colloidal suspension of nanoparticles in water, at pH 7.0, under isotonic conditions. The microparticles may be obtained by atomization of a solution or colloidal suspension of PO comprising at least one AP, may have a size of between 0.5 and 100 microns, and may be dispersible in colloidal suspension. | 2014-04-17 |
20140105994 | Microencapsulated Amino Acid Composition and the Method of Manufacturing the Microencapsulated Amino Acid Composition - The invention relates to a microencapsulated amino acid composition and methods of manufacturing this composition. Amino acids, such as branched-chain amino acids, have low water solubility, poor hydrophilicity, and poor stability. Amino acids are thus difficult to be digested and absorbed. Consequently amino acids can hardly meet human needs of consuming. This microencapsulated amino acid composition that can quickly disperse and dissolve in cold water, resulting clear solution. The method includes (1) adding coating agents, wetting agents, or other excipients to the amino acid mixture, (2) modifying the surface of microencapsulated particles to considerably accelerate the wetting speed. In this composition, the weight ratio of amino acids and excipients is from 100/0.1 to 100/10.0. | 2014-04-17 |
20140105995 | SILK FIBROIN SYSTEMS FOR ANTIBIOTIC DELIVERY - The present invention provides for silk fibroin-based compositions comprising one or more antibiotic agents for prevention or treatment of microbial contamination, methods of making antibiotic-containing silk scaffold, methods of stabilizing antibiotics in silk scaffolds, and methods for preventing or treating microbial contamination using the antibiotic-containing compositions. Various methods may be used to embed the antibiotic(s) into the silk fibroin-based compositions. The antibiotic-containing compositions of the invention are particular useful for stabilizing antibiotics, preventing bacterial infections, and for medical implants, tissue engineering, drug delivery systems, or other pharmaceutical or medical applications. | 2014-04-17 |
20140105996 | Avian-Based Treatment - A method for treating or preventing proliferative skin disorders, cancers or pre-cancers comprising the step of: administering to a subject in need thereof a composition comprising avian extract EP-2 in a therapeutically effective concentration together with a pharmaceutically acceptable carrier and/or diluent. | 2014-04-17 |
20140105997 | GALECTIN-3 PLASMAPHERESIS THERAPY - The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer. | 2014-04-17 |
20140105998 | TREATMENT OF DISEASES - Methods of treatment of various non-demyelinating and demyelinating neural disorders are provided, comprising administering a serum composition obtained from a goat after challenge with an immunogen. Also provided are methods of treatment of certain autommune disorders using such a composition. | 2014-04-17 |
20140105999 | OIL COMPOSITION, FORMULATIONS COMPRISING THE OIL COMPOSITION, AND THE USE THEREOF TO REDUCE ACCUMULATION OF VISCERAL FAT, IMPROVE GLUCOSE TOLERANCE, AND PREVENT OR TREAT OBESITY RELATED DISEASES AND DISORDERS - This invention relates to an oil composition, preferably obtained from a copepod, and the use thereof to reduce accumulation of visceral fat and counteract impairment of heart function caused by obesity inducing Western diets. The oil composition of the present invention can thus be used to reduce abdominal obesity and improve glucose tolerance and thus to reduce the risk of obesity related diseases such as but not limited to type 2 diabetes or cardiovascular disease, or to prevent or treat such diseases. | 2014-04-17 |
20140106000 | METHOD FOR FILLING BONE CAVITY FORMATIONS WITH CALCIUM - A method is proposed for filling cavity formations in metaphyseal (trabecular) bone sections with calcium and for preventing secretions of calcium therefrom. The proposed method consists in supplying drone brood to an organism in combination with supplying calcium to the organism. Existing methods for saturating an organism with calcium do not achieve the desired result. | 2014-04-17 |
20140106001 | MARINE EXTRACT COMPOSITIONS AND METHODS OF USE - Compositions comprising extracts from marine organisms show beneficial effects on skin ailments. Fine lines, wrinkles, and sagging in skin are improved with the application of compositions with marine extracts. Production of collagen, elastin and hyaluronic acid are increased after application of the compositions. | 2014-04-17 |
20140106002 | HOMEOPATHIC COMPOSITION AND METHOD FOR THE TREATMENT OF SKIN IRRITATIONS AND OTHER SKIN DISEASES - A homeopathic composition and method for treating a variety of skin irritations, wounds, and diseases is disclosed. The homeopathic composition may contain as active ingredients salicyclic acid, trona or one of its salts, and at least one homeopathic agent. | 2014-04-17 |
20140106003 | Thioxanthone-Based Autophagy Inhibitor Therapies to Treat Cancer - The present specification provides compositions comprising a thioxanthone-based autophagy inhibitor and/or a cancer therapeutic autophagy inducing compound, pharmaceutical kits comprising these compositions, and methods of treating cancer using such compounds, compositions and kits. Additionally, the present specification provides methods of treating cancer using a thioxanthone-based autophagy inhibitor and a radiotherapy. | 2014-04-17 |
20140106004 | HEMOGLOBIN-BASED OXYGEN CARRIER-CONTAINING PHARMACEUTICAL COMPOSITION FOR CANCER TARGETING TREATMENT AND PREVENTION OF CANCER RECURRENCE - The present invention provides a pharmaceutical composition containing a hemoglobin-based oxygen carrier for treating cancer, preventing recurrence and metastasis of cancerous tumor. The composition can be used alone or in combination with at least one chemotherapeutic agent such as 5FU, Bortezomib, doxorubicin, cisplatin, or any combination thereof. The hemoglobin-based oxygen carrier in the composition is capable of targeting a surface receptor expressed on cancerous cells and facilitating the uptake of both hemoglobin-based oxygen carrier and the chemotherapeutic agent by the cancerous cells via a receptor-mediated mechanism. The hemoglobin-based oxygen carrier inhibits the expression of hypoxic response elements such as HIF1α, VEGF, ET1, VHL, etc. The pharmaceutical composition of the present invention is also useful for inducing the apoptosis or cell death of a type of self-renewing and tumor-initiating cells called cancer stem cells which are located in the hypoxic niche of a cancerous tumor. | 2014-04-17 |
20140106005 | Compositions And Methods Of Use Of Phorbol Esters In The Treatment Of Neoplasms - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases. | 2014-04-17 |
20140106006 | Synergistic Combination For The Treatment of Type 2 Diabetes Mellitus - The invention relates to a synergistic combination of trivalent chromium, biotin and American ginseng, which is effective for the treatment of type 2 diabetes mellitus. It also relates to dietetic compositions which include such combination that are appropriate for treatment of type 2 diabetes mellitus in obese patients. It also relates to the use of said combination for the preparation of a medicament for the treatment of that type of diabetes. | 2014-04-17 |
20140106007 | ELECTROCHEMICAL ACTIVATION OF WATER - The methods, systems, and apparatus disclosed herein employ natural, common salts, that are electrochemically activated (ECA) in an aqueous solution to result in an ECA product solution that is safe and non-toxic. Various implementations include a portable table top design having a portable receptacle that includes electrodes. The receptacle fits on a base which provides power for the electrochemical activation. Continuous flow designs receive input water, mix the water with reactants then pass the solution between electrodes to electrochemically activate the solution. Using a metal halide salt, such as NaCl with citric acid may produce a sanitizer or disinfectant. Using a metal carbonate salt, such as K | 2014-04-17 |
20140106008 | GLYCEROL COMPOSITIONS AND SOLUTIONS - The invention discloses the use of a treatment composition for preventing, or reducing, the production of contaminants selected from microorganisms and microorganism-produced toxins by contacting the substrate with the composition. The composition comprises a water glycerol mixture and calcium hydroxide in which the percentage by mass of glycerol in the water glycerol mixture is between 5% and 95%, at least some of the calcium hydroxide is dissolved in the water glycerol mixture and the concentration of the dissolved calcium hydroxide in the water glycerol mixture is at least 1.5 times higher than the maximum concentration of dissolved calcium hydroxide which can be obtained in water alone, thereby preventing or reducing the production of the contaminants. The extent of the prevention or reduction is at least 1.5 times more than the corresponding prevention or reduction produced by a treatment composition comprising water and calcium hydroxide only. | 2014-04-17 |
20140106009 | METHODS AND COMPOSITIONS FOR MAINTAINING AND IMPROVING THE HEALTH OF SKIN - Biologically active extracts of one or more of | 2014-04-17 |
20140106010 | Blend of Green and Black Extracts for the Promotion of Health Benefits - A method of improving urological health in a human, including administration to the human of an effective amount of a water-extracted extract of both green and black tea. | 2014-04-17 |
20140106011 | USE OF TEA-DERIVED, THEAFLAVIN ENRICHED EXTRACT TO INCREASE PERFORMANCE AND REDUCE EXERCISE RECOVERY TIME - This invention provides various methods such as a method for enhancing athletic exercise performance of a subject by administering to the subject a composition comprising a physiologically acceptable carrier and an extract of tea, wherein the extract comprises at least 20% by weight of theaflavins and wherein the composition is administered in an amount effective to enhance the subject's athletic performance. | 2014-04-17 |
20140106012 | COMPOSITIONS AND METHODS USEFUL FOR TREATING PEDICULOSIS - Disclosed are compositions and methods that in some embodiments are useful in the treatment of pediculosis. | 2014-04-17 |
20140106013 | MEDICAL COMPOSITION FOR INHIBITING THE GROWTH OF CANCER STEM CELLS - A medical composition for inhibiting the growth of cancer stem cells is disclosed. The medical composition is prepared by mixing herbal medicines with water or alcohol, followed by heating and extraction to obtain a filtrate. One of the medical compositions according to the present invention includes: | 2014-04-17 |